{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:31:54Z","timestamp":1792801914775,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T00:00:00Z","timestamp":1433548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T00:00:00Z","timestamp":1433548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Patients undergoing immunosuppressive therapy are at increased risk of infection. Community-acquired pneumonia and invasive pneumococcal disease account for substantial morbidity and mortality in this population and may be prevented by vaccination. Ideally, immunization to pneumococcal antigens should take place before the start of immunosuppressive treatment. Often, however, the treatment cannot be delayed. Little is known about the efficacy of pneumococcal vaccines during immunosuppressive treatment. The objectives of this study were to determine the percentage of vaccine-na\u00efve, immunosuppressed adults with inflammatory diseases seroprotected against <jats:italic>Streptococcus pneumoniae<\/jats:italic> and to assess factors associated with the immunogenicity, clinical impact and safety of 23-valent pneumococcal polysaccharide vaccine (PPV) in seronegative subjects.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>This observational study included patients 18 years of age and older who were receiving prednisone \u226520 mg\/day or other immunosuppressive drugs. Exclusion criteria were PPV administration in the previous 5 years, intravenous immunoglobulins and pregnancy. Serum immunoglobulin G (IgG) antibody levels against six pneumococcal serotypes were measured. Seropositivity was defined as IgG of 0.5 \u03bcg\/ml or greater for at least four of six serotypes. Seronegative patients received PPV, and seropositive patients were included as a comparison group. Vaccine response and tolerance were assessed after 4\u20138 weeks. Disease activity was evaluated on the basis of the Physician Global Assessment scores. Serology was repeated after 1 year, and information on any kind of infection needing medical attention was collected. Outcomes were the proportion of seropositivity and infections between vaccinated and unvaccinated patients.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Of 201 included patients, 35 received high-dose corticosteroids and 181 were given immunosuppressive drugs. Baseline seronegativity in 60 (30 %) patients was associated with corticotherapy and lower total IgG. After PPV, disease activity remained unchanged or decreased in 81 % of patients, and 87 % became seropositive. After 1 year, 67 % of vaccinated compared with 90 % of observed patients were seropositive (<jats:italic>p<\/jats:italic> &lt; 0.001), whereas the rate of infections did not differ between groups. Those still taking prednisone \u226510 mg\/day tended to have poorer serological responses and had significantly more infections.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>PPV was safe and moderately effective based on serological response. Seropositivity to pneumococcal antigens significantly reduced the risk of infections. Sustained high-dose corticosteroids were associated with poor vaccine response and more infections.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-015-0663-9","type":"journal-article","created":{"date-parts":[[2015,6,5]],"date-time":"2015-06-05T11:16:15Z","timestamp":1433502975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases \u2013 a longitudinal study"],"prefix":"10.1186","volume":"17","author":[{"given":"Lara","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Francis","family":"Gerstel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Poncet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire-Anne","family":"Siegrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Laffitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Gabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg Dieter","family":"Seebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Ribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,6]]},"reference":[{"key":"663_CR1","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O\u2019Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287\u201393.","journal-title":"Arthritis Rheum."},{"key":"663_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/jech-2011-200168","volume":"66","author":"CJ Wotton","year":"2012","unstructured":"Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health. 2012;66:1177\u201381.","journal-title":"J Epidemiol Community Health."},{"key":"663_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.berh.2007.05.003","volume":"21","author":"SM Naz","year":"2007","unstructured":"Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21:871\u201383.","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"663_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/art.21568","volume":"54","author":"F Wolfe","year":"2006","unstructured":"Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628\u201334.","journal-title":"Arthritis Rheum."},{"key":"663_CR5","first-page":"1832","volume":"34","author":"P Coyne","year":"2007","unstructured":"Coyne P, Hamilton J, Heycock C, Saravanan V, Coulson E, Kelly CA. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol. 2007;34:1832\u20136.","journal-title":"J Rheumatol."},{"key":"663_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jbspin.2010.02.009","volume":"77","author":"A Ruyssen-Witrand","year":"2010","unstructured":"Ruyssen-Witrand A, Fautrel B, Saraux A, Le-Lo\u00ebt X, Pham T. Infections induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. 2010;77:246\u201351.","journal-title":"Joint Bone Spine."},{"key":"663_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/rheumatology\/kep101","volume":"48","author":"A McLean-Tooke","year":"2009","unstructured":"McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence? Rheumatology. 2009;48:867\u201371.","journal-title":"Rheumatology."},{"key":"663_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.autrev.2008.07.010","volume":"8","author":"M Cutolo","year":"2008","unstructured":"Cutolo M, Seriolo B, Pizzorni C, Secchi ME, Soldano S, Paolino S, et al. Use of glucocorticoids and risk of infections. Autoimmun Rev. 2008;8:153\u20135.","journal-title":"Autoimmun Rev."},{"key":"663_CR9","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275\u201385.","journal-title":"JAMA."},{"key":"663_CR10","doi-asserted-by":"publisher","first-page":"9203","DOI":"10.1073\/pnas.97.16.9203","volume":"97","author":"K Koetz","year":"2000","unstructured":"Koetz K, Bryl E, Spickschen K, O\u2019Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A. 2000;97:9203\u20138.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"663_CR11","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/rheumatology\/keq183","volume":"49","author":"JF Rahier","year":"2010","unstructured":"Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology. 2010;49:1815\u201327.","journal-title":"Rheumatology."},{"key":"663_CR12","first-page":"816","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","unstructured":"Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"663_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/ard.2010.137216","volume":"70","author":"S van Assen","year":"2011","unstructured":"van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414\u201322.","journal-title":"Ann Rheum Dis."},{"key":"663_CR14","unstructured":"InfoVac: La ligne directe d\u2019information sur la vaccination! http:\/\/www.infovac.ch\/. Accessed 15 June 2015."},{"key":"663_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2474-8-58","volume":"8","author":"E Sowden","year":"2007","unstructured":"Sowden E, Mitchell WS. An audit of influenza and pneumococcal vaccination in rheumatology outpatients. BMC Musculoskelet Disord. 2007;8:58.","journal-title":"BMC Musculoskelet Disord."},{"key":"663_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1136\/ard.2006.060285","volume":"66","author":"J Pradeep","year":"2007","unstructured":"Pradeep J, Watts R, Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:837\u20138.","journal-title":"Ann Rheum Dis."},{"key":"663_CR17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4049\/jimmunol.141.2.410","volume":"141","author":"GJ Rosenthal","year":"1988","unstructured":"Rosenthal GJ, Weigand GW, Germolec DR, Blank JA, Luster MI. Suppression of B cell function by methotrexate and trimetrexate: evidence for inhibition of purine biosynthesis as a major mechanism of action. J Immunol. 1988;141:410\u20136.","journal-title":"J Immunol."},{"key":"663_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11908-011-0183-y","volume":"13","author":"LG Visser","year":"2011","unstructured":"Visser LG. TNF-\u03b1 antagonists and immunization. Curr Infect Dis Rep. 2011;13:243\u20137.","journal-title":"Curr Infect Dis Rep."},{"key":"663_CR19","doi-asserted-by":"publisher","first-page":"CD000422","DOI":"10.1002\/14651858.CD000422.pub3","volume":"1","author":"S Moberley","year":"2013","unstructured":"Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422. doi:10.1002\/14651858.CD000422.pub3.","journal-title":"Cochrane Database Syst Rev."},{"key":"663_CR20","first-page":"306","volume":"11","author":"E McDonald","year":"1984","unstructured":"McDonald E, Jarrett MP, Schiffman G, Grayzel AI. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol. 1984;11:306\u20138.","journal-title":"J Rheumatol."},{"key":"663_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0889-857X(05)70087-9","volume":"25","author":"RK Avery","year":"1999","unstructured":"Avery RK. Vaccination of the immunosuppressed adult patient with rheumatologic disease. Rheum Dis Clin North Am. 1999;25:567\u201384.","journal-title":"Rheum Dis Clin North Am."},{"key":"663_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/rheumatology\/ker388","volume":"51","author":"T Hugle","year":"2012","unstructured":"Hugle T, Bircher A, Walker UA. Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Beh\u00e7et\u2019s disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine. Rheumatology. 2012;51:761\u20132.","journal-title":"Rheumatology."},{"key":"663_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.autrev.2006.09.005","volume":"6","author":"O Elkayam","year":"2007","unstructured":"Elkayam O, Ablin J, Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmun Rev. 2007;6:312\u20134.","journal-title":"Autoimmun Rev."},{"key":"663_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.autrev.2008.07.007","volume":"8","author":"F Conti","year":"2008","unstructured":"Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev. 2008;8:124\u20138.","journal-title":"Autoimmun Rev."},{"key":"663_CR25","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/ard.2010.144451","volume":"70","author":"E Coulson","year":"2011","unstructured":"Coulson E, Saravanan V, Hamilton J, So KL, Morgan L, Heycock C, et al. Pneumococcal antibody levels after Pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis. 2011;70:1289\u201391.","journal-title":"Ann Rheum Dis."},{"key":"663_CR26","first-page":"514","volume":"10","author":"CM Wernette","year":"2003","unstructured":"Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10:514\u20139.","journal-title":"Clin Diagn Lab Immunol."},{"key":"663_CR27","unstructured":"Swissmedic. Vaccins et produits sanguins autoris\u00e9s. http:\/\/www.swissmedic.ch\/. Accessed 15 June 2015."},{"key":"663_CR28","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1542\/peds.96.3.600","volume":"96","author":"GF Reed","year":"1995","unstructured":"Reed GF, Meade BD, Steinhoff MC. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics. 1995;96:600\u20133.","journal-title":"Pediatrics."},{"key":"663_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2307\/2531957","volume":"43","author":"PC O\u2019Brien","year":"1987","unstructured":"O\u2019Brien PC, Fleming TR. A paired Prentice\u2013Wilcoxon test for censored paired data. Biometrics. 1987;43:169\u201380.","journal-title":"Biometrics."},{"key":"663_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1086\/338043","volume":"34","author":"O Elkayam","year":"2002","unstructured":"Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis. 2002;34:147\u201353.","journal-title":"Clin Infect Dis."},{"key":"663_CR31","first-page":"272","volume":"34","author":"JL Kaine","year":"2007","unstructured":"Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34:272\u20139.","journal-title":"J Rheumatol."},{"key":"663_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2133.2004.06070.x","volume":"151","author":"W Sterry","year":"2004","unstructured":"Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151:3\u201317.","journal-title":"Br J Dermatol."},{"key":"663_CR33","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/art.30325","volume":"63","author":"C Gabay","year":"2011","unstructured":"Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011;63:1486\u201396.","journal-title":"Arthritis Rheum."},{"key":"663_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","volume":"45","author":"MC Kapetanovic","year":"2006","unstructured":"Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, J\u00f6nsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology. 2006;45:106\u201311.","journal-title":"Rheumatology."},{"key":"663_CR35","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1016\/j.vaccine.2008.04.028","volume":"26","author":"LB Gelinck","year":"2008","unstructured":"Gelinck LB, van der Bijl AE, Visser LG, Huizinga TW, van Hogezand RA, Rijkers GT, et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine. 2008;26:3528\u201333.","journal-title":"Vaccine."},{"key":"663_CR36","first-page":"952","volume":"34","author":"S Visvanathan","year":"2007","unstructured":"Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol. 2007;34:952\u20137.","journal-title":"J Rheumatol."},{"key":"663_CR37","first-page":"1356","volume":"31","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol. 2004;31:1356\u201361.","journal-title":"J Rheumatol."},{"key":"663_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/BOR.0b013e3282ffdeca","volume":"20","author":"HP Brezinschek","year":"2008","unstructured":"Brezinschek HP, Hofstaetter T, Leeb BF, Haindl P, Graninger WB. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor \u03b1 therapy and methotrexate. Curr Opin Rheumatol. 2008;20:295\u20139.","journal-title":"Curr Opin Rheumatol."},{"key":"663_CR39","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3181\/00379727-173-41643","volume":"173","author":"MA Mufson","year":"1983","unstructured":"Mufson MA, Krause HE, Schiffman G. Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc Soc Exp Biol Med. 1983;173:270\u20135.","journal-title":"Proc Soc Exp Biol Med."},{"key":"663_CR40","first-page":"64","volume":"927","author":"World Health Organization Expert Committee on Biological Standardization","year":"2005","unstructured":"World Health Organization Expert Committee on Biological Standardization. Recommendations for the production and control of pneumococcal conjugate vaccines. World Health Organ Tech Rep Ser. 2005;927:64\u201398.","journal-title":"World Health Organ Tech Rep Ser"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0663-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-015-0663-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0663-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0663-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:04:43Z","timestamp":1728921883000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-015-0663-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["663"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0663-9","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,6]]},"assertion":[{"value":"10 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"151"}}